Education
About Us
Working with TipRanks
Follow Us
Xenon (XENE)
NASDAQ:XENE
XENE Analyst Ratings
Strong Buy
14 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
XENE Stock 12 Month Forecast
Average Price Target
$55.59
▲(35.06% Upside)
| Highest Price Target$65.00 | Average Price Target$55.59 | Lowest Price Target$44.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
J.P. Morgan
$57→$60
Buy
45.77%
Upside
Reiterated
11/18/25
H.C. Wainwright
$40.04→$53
Buy
28.77%
Upside
Reiterated
11/14/25
Evercore ISI
$55
Buy
33.62%
Upside
Reiterated
11/04/25
William Blair
―
Buy
―
Reiterated
11/04/25
Bank of America Securities
$49→$50
Buy
21.48%
Upside
Reiterated
11/04/25
Stifel Nicolaus
$60
Buy
45.77%
Upside
Reiterated
11/04/25
Needham
$55
Buy
33.62%
Upside
Assigned
11/04/25
RBC Capital
$55→$58
Buy
40.91%
Upside
Reiterated
11/04/25
Wells Fargo
$48→$44
Buy
6.90%
Upside
Reiterated
11/04/25
TD Cowen
―
Buy
―
Reiterated
11/03/25
Leerink Partners
―
Buy
―
Reiterated
10/07/25
Chardan Capital
$55
Buy
33.62%
Upside
Reiterated
10/07/25
Bloom Burton
$56.5
Buy
37.27%
Upside
Reiterated
10/07/25
Promising Outlook on Xenon Pharmaceuticals: Buy Rating Backed by Innovative Pain Treatment Developments11:49 AM F r o m : Research S e n t : 1:55 PM S u b j e c t : Xenon Pharmaceu cals Inc. (NASDAQ:XENE, $39.55). Webinar Encouraging. Both have advanced into phase 1 testing in healthy volunteers with results expected next year. Trial design was not discussed in detail, however, results should include safety/tolerability, PK and possibly PD and induced pain response endpoints. Based on the emerging profiles of XEN1120 and XEN1701, both could be attractive in multiple pain settings including acute and chronic nociceptive (tissue injury) as well as neuropathic (nervous system dysfunction) pain - together affecting 125-130 million individuals in the U.S.
Jefferies
$65
Buy
57.92%
Upside
Reiterated
10/07/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
J.P. Morgan
$57→$60
Buy
45.77%
Upside
Reiterated
11/18/25
H.C. Wainwright
$40.04→$53
Buy
28.77%
Upside
Reiterated
11/14/25
Evercore ISI
$55
Buy
33.62%
Upside
Reiterated
11/04/25
William Blair
―
Buy
―
Reiterated
11/04/25
Bank of America Securities
$49→$50
Buy
21.48%
Upside
Reiterated
11/04/25
Stifel Nicolaus
$60
Buy
45.77%
Upside
Reiterated
11/04/25
Needham
$55
Buy
33.62%
Upside
Assigned
11/04/25
RBC Capital
$55→$58
Buy
40.91%
Upside
Reiterated
11/04/25
Wells Fargo
$48→$44
Buy
6.90%
Upside
Reiterated
11/04/25
TD Cowen
―
Buy
―
Reiterated
11/03/25
Leerink Partners
―
Buy
―
Reiterated
10/07/25
Chardan Capital
$55
Buy
33.62%
Upside
Reiterated
10/07/25
Bloom Burton
$56.5
Buy
37.27%
Upside
Reiterated
10/07/25
Promising Outlook on Xenon Pharmaceuticals: Buy Rating Backed by Innovative Pain Treatment Developments11:49 AM F r o m : Research S e n t : 1:55 PM S u b j e c t : Xenon Pharmaceu cals Inc. (NASDAQ:XENE, $39.55). Webinar Encouraging. Both have advanced into phase 1 testing in healthy volunteers with results expected next year. Trial design was not discussed in detail, however, results should include safety/tolerability, PK and possibly PD and induced pain response endpoints. Based on the emerging profiles of XEN1120 and XEN1701, both could be attractive in multiple pain settings including acute and chronic nociceptive (tissue injury) as well as neuropathic (nervous system dysfunction) pain - together affecting 125-130 million individuals in the U.S.
Jefferies
$65
Buy
57.92%
Upside
Reiterated
10/07/25
Best Analysts Covering Xenon
1 Month
xxx
Success Rate
6/11 ratings generated profit
Average Return
-0.12%
reiterated a xxx
rating 20 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 54.55% of your transactions generating a profit, with an average return of -0.12% per trade.
3 Months
xxx
Success Rate
14/23 ratings generated profit
Average Return
+15.73%
assigned a xxx
rating 20 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.87% of your transactions generating a profit, with an average return of +15.73% per trade.
1 Year
Success Rate
14/17 ratings generated profit
Average Return
+29.09%
reiterated a buy rating 2 months ago
Copying Andrew Tsai's trades and holding each position for 1 Year would result in 82.35% of your transactions generating a profit, with an average return of +29.09% per trade.
2 Years
xxx
Success Rate
12/17 ratings generated profit
Average Return
+39.39%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 70.59% of your transactions generating a profit, with an average return of +39.39% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
XENE Analyst Recommendation Trends
Rating
Jun 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
14
17
9
8
4
Buy
6
11
8
15
19
Hold
1
0
0
0
0
Sell
2
0
0
0
0
Strong Sell
0
0
0
0
0
total
23
28
17
23
23
Each month's total comprises the sum of three months' worth of ratings.
XENE Financial Forecast
XENE Stock Forecast FAQ
What is XENE’s average 12-month price target, according to analysts?
Based on analyst ratings, Xenon’s 12-month average price target is 55.59.
What is XENE’s upside potential, based on the analysts’ average price target?
Xenon has 35.06% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is XENE a Buy, Sell or Hold?
Xenon has a consensus rating of Strong Buy which is based on 14 buy ratings, 0 hold ratings and 0 sell ratings.
What is Xenon’s price target?
The average price target for Xenon is 55.59. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $65.00 ,the lowest forecast is $44.00. The average price target represents 35.06% Increase from the current price of $41.16.
The highest analyst price target is $65.00 ,the lowest forecast is $44.00. The average price target represents 35.06% Increase from the current price of $41.16.
What do analysts say about Xenon?
Xenon’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
How can I buy shares of XENE?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.